Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 5
Submit an article Journal homepage
487
Views
15
CrossRef citations to date
0
Altmetric
Letter

High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial

Anna LaurellDepartment of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala, SwedenCorrespondence[email protected]
,
Arne KolstadDepartment of Oncology, Rikshospitalet, Oslo, Norway
,
Mats JerkemanDepartment of Oncology, Lund University Hospital, Lund, Sweden
,
Riikka RätyDepartment of Hematology, Helsinki University Central Hospital, Helsinki, Finland
&
Christian H. GeislerDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark
Pages 1206-1208 | Received 28 May 2013, Accepted 12 Jul 2013, Published online: 28 Aug 2013

References

  • Andersen NS, Pedersen L, Elonen E, et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003;71: 73–80.
  • Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
  • Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010;115:1530–1533.
  • Kolstad A, Laurell A, Jerkeman M, et al. Nordic MCL3 study: Zevalin combined with high-dose chemotherapy followed by autologous stem cell support as late intensification for mantle cell lymphoma (MCL) patients < 66 years not in CR after induction chemoimmunotherapy: no benefit of Zevalin. Blood 2012;120(Suppl. 1): Abstract 147.
  • Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
  • Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012;158:355–362.
  • Le Gouill S, Callanan M, Macintyre E, et al. Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, a Lysa study. Blood 2012;120(Suppl. 1): Abstract 152.
  • Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood 2012;120(Suppl. 1): Abstract 150.
  • Forbes A, Farrell K, McKay P, et al. High dose cytarabine with rituximab is an effective first-line therapy for mantle cell lymphoma and produces ample stem cell harvest yields after multiple chemotherapy cycles. Leuk Lymphoma 2013;54:2303–2305.
  • Budde LE, Guthrie KA, Till BG, et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 2011;29:3023–3029.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.